EQT Life Sciences and Nextech Lead $183 Million Series C for Electra Therapeutics

October 22, 2025
Electra Therapeutics has raised $183 million in a Series C financing co-led by EQT Life Sciences and Nextech, with participation from Sanofi and other investors, to advance its immunology and cancer programs.

Electra Therapeutics has raised USD 183 million in Series C financing co-led by EQT Life Sciences and Nextech, with participation from Sanofi, HBM Healthcare Investments, Mubadala Capital, and existing investors, announced in a press release.

The funding will support a registrational Phase 2/3 clinical study of Electra’s lead program, ELA026, in secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory condition with no approved therapies. The study aims to confirm earlier Phase 1b results showing 100 percent survival at 8 weeks in frontline-treated patients.

Electra will also use the proceeds to expand ELA026 into hematologic cancers and to advance its second program, ELA822, which targets immune-mediated diseases. ELA026 has received FDA Breakthrough Therapy and EMA Priority Medicines designations for sHLH.

EQT Life Sciences partner Christoph Broja will join Electra’s board as an observer, supporting the company’s ongoing clinical and development initiatives.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

AI Funding News Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Funding

10/22
Cohere Plans IPO as CEO Aidan Gomez Says Listing Could Come 'Soon'
10/22
Sinecure Acquires The Second Shift to Expand AI-Powered Talent Platform
10/22
Second Nature Raises $22M Series B to Expand AI Roleplay Training Platform
10/21
Veeam to Acquire Securiti AI for $1.7 Billion
10/21
Hyro Raises $45 Million to Expand AI Agents for Healthcare

More from: Life Sciences

10/22
Adtalem and Google Cloud Launch AI Credentials Program for Healthcare Professionals
10/21
Hyro Raises $45 Million to Expand AI Agents for Healthcare
10/21
DrugBank Appoints Lisa Downey as CEO, Co-Founder Mike Wilson Moves to Chief Product Role
10/21
Lightbeam Health Solutions Reports $444 Million in ACO Savings for 2024
10/21
Brook.ai Names Former Teladoc COO Mike Waters as Chairman of the Board

Subscribe to AI Funding Brief

AI Token Webinar

Whitepaper

Governing the Future: A Strategic Framework for AI Adoption in Financial Institutions

This whitepaper explores the transformative impact of artificial intelligence on the financial industry, focusing on the governance challenges and regulatory demands faced by banks. It provides a strategic framework for AI adoption, emphasizing the importance of a unified AI approach to streamline compliance and reduce operational costs. The document offers actionable insights and expert recommendations for banks with fewer than 2,000 employees to become leaders in compliant, customer-centric AI.

Read more

You May Also Like